A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Key Inclusion Criteria:

• Male or female participants 40 to 85 years of age, inclusive, at the time ofinformed consent.

• Meet the diagnostic criteria for "Probable PD" as assessed on the Movement DisorderSociety (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator.

• Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 yearsof the Screening Visit

Key Exclusion Criteria:

• Medical history indicating a Parkinsonian syndrome other than idiopathic PD,including, but not limited to, progressive supranuclear gaze palsy, multiple systematrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia.

• Diagnosis of clinically significant central nervous system (CNS) disease other thanPD.

• Participants who are current smokers (defined as smoking [in any form, e.g., tobaccosmoke, electronic cigarettes, etc.] within 6 months prior to the Baseline Visit).

• Treatment with PD medication(s) for a total of more than 28 days or treatment withany PD medication within 90 days of the Baseline Visit.

• Any other condition(s) that may compromise participant safety, interfere with studyconduct, or jeopardize the potential proper interpretation of study results, in theopinion of the investigator.